If the FeNO level is not raised, it is recommended that the patient be offered either a Long-Acting Muscarinic Antagonist ...

This comes after the Commission for Air Quality Management (CAQM) on Saturday invoked measures under stage IV of Graded ...

"There’s a big opportunity for MAHA to include real-world experts in future studies and analysis," writes Dr. James S. Gordon.

Indiana University School of Medicine researchers are taking a closer look at how young patients respond to biologic ...

The MHRA has approved depemokimab as an add-on treatment for severe asthma and chronic rhinosinusitis with nasal polyps.

The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.

GSK Plc said it won US approval for a drug to treat severe asthma, boosting its prospects as a potential blockbuster.

The FDA approved depemokimab as an add-on maintenance treatment in patients aged at least 12 years with severe asthma and an ...

The Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa), an interleukin-5 antagonist, for add-on maintenance treatment of severe asthma characterized by an eosinophilic ...

If you have out-of-control debt, you probably have made an attempt or two to pay it down. But a debt management plan (or DMP) is a much more organized plan of attack. You usually enroll in a DMP ...

FDA approves GSK's Exdensur for severe eosinophilic asthma, backed by Phase 3 data showing up to 58% fewer asthma attacks ...

FDA approves 2-dose biologic Exdensur for severe eosinophilic asthma in patients 12 and older, reducing exacerbations and hospital visits.